XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announces it has successfully completed its previously announced acquisition of all the outstanding common shares of LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) with a nominal value of €0.12 per share (“Shares”). “The acquisition of LAVA Therapeutics reinforces XOMA’s philosophy of ‘strength in numbers’, adding two early-stage bispecific antibodies in collaboration with well-established oncology partners, Johnson and Johnson and Pfizer,” stated Owen Hughes, Chief Executive Officer of XOMA Royalty.
Read the full article: XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. //
Source: https://www.globenewswire.com/news-release/2025/11/21/3192735/7281/en/XOMA-Royalty-Announces-Closing-of-Transactions-to-Acquire-LAVA-Therapeutics-N-V.html